Literature DB >> 12152804

Visual evoked potentials in children with neurofibromatosis type 1.

Alessandro Iannaccone1, Richard A McCluney, Vickie R Brewer, Peter H Spiegel, June S Taylor, Natalie C Kerr, Enikö K Pivnick.   

Abstract

The purposes of this investigation were to determine: (a) if visual evoked potential (VEP) abnormalities could be identified in children with neurofibromatosis type 1 (NF1) with no evidence of optic pathway or brain neoplasias on MRI; and (b) if VEP abnormalities could be explained by the presence of hyperintense T2-weighted foci on MRI testing, known as unidentified bright objects (UBOs). To answer these questions, VEPs were recorded from 16 children with NF1 and compared to 13 normal subjects in the same age range tested with the same protocol. Pattern-reversal VEPs were recorded at four stimulus sizes both monocularly and binocularly, the latter to hemi-field stimuli. Flash VEPs were recorded in dark- and light-adapted conditions. VEP measurements and MRI readings for UBOs were conducted in a masked fashion. Ten of the 16 children with NF1 had abnormal VEPs to at least one of the four types of stimuli. Abnormalities included delayed responses (n=6), absent flash VEP P2 component (n=3), or both (n= 1). Abnormalities of the P2 component of the dark-adapted flash VEP were the most common finding (n=7), although no single testing strategy was able to identify all children with abnormal VEPs. UBOs were present in all children, demonstrating that their presence does not fully account for VEP abnormalities in children with NF1. This study also demonstrates that VEP abnormalities are present also in the absence of neoplasias of the optic pathways or of the brain. Our results are suggestive of a primary abnormality of visual processing in children with NF1.

Entities:  

Mesh:

Year:  2002        PMID: 12152804     DOI: 10.1023/a:1015719803719

Source DB:  PubMed          Journal:  Doc Ophthalmol        ISSN: 0012-4486            Impact factor:   2.379


  33 in total

1.  MRI in neurofibromatosis type I: using fluid-attenuated inversion recovery pulse sequences.

Authors:  H Yamanouchi; T Kato; H Matsuda; S Takashima; N Sakuragawa; M Arima
Journal:  Pediatr Neurol       Date:  1995-05       Impact factor: 3.372

2.  Neurofibromin, the neurofibromatosis type 1 Ras-GAP, is required for appropriate P0 expression and myelination.

Authors:  T Rosenbaum; H A Kim; Y L Boissy; B Ling; N Ratner
Journal:  Ann N Y Acad Sci       Date:  1999-09-14       Impact factor: 5.691

3.  Optic gliomas in neurofibromatosis type 1: role of visual evoked potentials.

Authors:  G T Liu; P Malloy; M Needle; P Phillips
Journal:  Pediatr Neurol       Date:  1995-01       Impact factor: 3.372

4.  Neurofibromatosis types 1 and 2: cranial MR findings.

Authors:  S Aoki; A J Barkovich; K Nishimura; B O Kjos; T Machida; P Cogen; M Edwards; D Norman
Journal:  Radiology       Date:  1989-08       Impact factor: 11.105

5.  Magnetic resonance findings and ophthalmologic abnormalities are correlated in patients with neurofibromatosis type 1 (NF1).

Authors:  M Sigorini; G Zuccoli; F Ferrozzi; E Bacchini; M E Street; P Piazza; M Rossi; R Virdis
Journal:  Am J Med Genet       Date:  2000-08-14

6.  Type 1 neurofibromatosis: a descriptive analysis of the disorder in 1,728 patients.

Authors:  J M Friedman; P H Birch
Journal:  Am J Med Genet       Date:  1997-05-16

7.  Neurofibromatosis type 1: pathologic substrate of high-signal-intensity foci in the brain.

Authors:  D P DiPaolo; R A Zimmerman; L B Rorke; E H Zackai; L T Bilaniuk; A T Yachnis
Journal:  Radiology       Date:  1995-06       Impact factor: 11.105

Review 8.  Learning disabilities, dyslexia, and vision: a subject review. Committee on Children with Disabilities, American Academy of Pediatrics (AAP) and American Academy of Ophthalmology (AAO), American Association for Pediatric Ophthalmology and Strabismus (AAPOS).

Authors: 
Journal:  Pediatrics       Date:  1998-11       Impact factor: 7.124

9.  Children and adolescents with neurofibromatosis 1: a behavioral phenotype.

Authors:  C V Dilts; J C Carey; J C Kircher; R O Hoffman; D Creel; K Ward; E Clark; C O Leonard
Journal:  J Dev Behav Pediatr       Date:  1996-08       Impact factor: 2.225

10.  The flash and pattern VEP as a diagnostic indicator of dementia.

Authors:  C E Wright; G F Harding; A Orwin
Journal:  Doc Ophthalmol       Date:  1986-01-31       Impact factor: 2.379

View more
  10 in total

Review 1.  Optical coherence tomography as a marker of vision in children with optic pathway gliomas.

Authors:  Ana Banc; Cristina Stan; Ioan Stefan Florian
Journal:  Childs Nerv Syst       Date:  2017-08-26       Impact factor: 1.475

Review 2.  Role of visual evoked potentials in the assessment and management of optic pathway gliomas in children.

Authors:  C Van Mierlo; W Spileers; E Legius; I Casteels; C Cassiman
Journal:  Doc Ophthalmol       Date:  2013-07-25       Impact factor: 2.379

3.  Neuroretinal dysfunction in patients affected by neurofibromatosis type 1.

Authors:  Antonietta Moramarco; Luca Lucchino; Fabiana Mallone; Michela Marcelli; Ludovico Alisi; Vincenzo Roberti; Sandra Giustini; Alessandro Lambiase; Marcella Nebbioso
Journal:  Int J Ophthalmol       Date:  2022-05-18       Impact factor: 1.645

Review 4.  Visual function tests including the role of optical coherence tomography in neurofibromatosis 1.

Authors:  Daphna Mezad-Koursh; Anat Bachar Zipori; Dinah Zur; Lior Degabli; Meital Ben-Dov; Ainat Klein
Journal:  Childs Nerv Syst       Date:  2020-08-04       Impact factor: 1.475

Review 5.  Ophthalmological assessment of children with neurofibromatosis type 1.

Authors:  Catherine Cassiman; Eric Legius; Werner Spileers; Ingele Casteels
Journal:  Eur J Pediatr       Date:  2013-05-25       Impact factor: 3.183

6.  Visual function assessed by visually evoked potentials in optic pathway low-grade gliomas with and without neurofibromatosis type 1.

Authors:  Patrícia de Freitas Dotto; Adriana Berezovsky; Andrea Maria Cappellano; Nasjla Saba da Silva; Paula Yuri Sacai; Frederico Adolfo B Silva; Arthur Gustavo Fernandes; Daniel Martins Rocha; Solange Rios Salomão
Journal:  Doc Ophthalmol       Date:  2018-05-15       Impact factor: 2.379

7.  Detection of tumor progression in optic pathway glioma with and without neurofibromatosis type 1.

Authors:  John P Kelly; Avery H Weiss
Journal:  Neuro Oncol       Date:  2013-10-06       Impact factor: 12.300

8.  Bilateral paraneoplastic optic neuropathy and unilateral retinal compromise in association with prostate cancer: a differential diagnostic challenge in a patient with unexplained visual loss.

Authors:  Giovannella Carboni; Gina Forma; April D Bond; Grazyna Adamus; Alessandro Iannaccone
Journal:  Doc Ophthalmol       Date:  2012-05-09       Impact factor: 2.379

9.  Functional outcome measures for NF1-associated optic pathway glioma clinical trials.

Authors:  Michael J Fisher; Robert A Avery; Jeffrey C Allen; Simone L Ardern-Holmes; Larissa T Bilaniuk; Rosalie E Ferner; David H Gutmann; Robert Listernick; Staci Martin; Nicole J Ullrich; Grant T Liu
Journal:  Neurology       Date:  2013-11-19       Impact factor: 9.910

Review 10.  Electrophysiological and Behavioral Evidence for Hyper- and Hyposensitivity in Rare Genetic Syndromes Associated with Autism.

Authors:  Anastasia Neklyudova; Kirill Smirnov; Anna Rebreikina; Olga Martynova; Olga Sysoeva
Journal:  Genes (Basel)       Date:  2022-04-11       Impact factor: 4.141

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.